Prognostic influence of prior chronic obstructive pulmonary disease in patients admitted for their first episode of acute heart failure
- 148 Downloads
Chronic obstructive pulmonary disease (COPD) is a frequent comorbidity in heart failure (HF) patients. Whether a prior COPD diagnosis influences patients’ prognosis in early stages of HF is unknown. We reviewed patients > 50 years old admitted because of a first episode of acute HF. We divided the sample into two groups according to the existence of a prior diagnosis of COPD. We used regression analysis to identify the baseline patients’ characteristics associated with the presence of COPD, and Cox mortality analysis to identify baseline and discharge data related to higher risk of a combined outcome of 1-year all-cause readmission or mortality. Finally, 985 patients were included in the analysis; 212 (21.5%) with a prior diagnosis of COPD. Baseline characteristics were similar between both groups except for a much higher prevalence of male gender, higher number of chronic therapies, and lower prevalence of atrial fibrillation among COPD patients. The combined primary outcome is significantly more prevalent in COPD patients (68.4 vs. 59.8%, p = 0.022). Cox analysis identified this prior diagnosis of COPD (HR 1.282, 95% CI 1.063–1.547; p = 0.001) as an independent risk factor for 1-year readmission and mortality, together with older age, higher admission creatinine and potassium values, and a higher number of chronic therapies. Our study confirms that in a “real-life” cohort of elderly patients experiencing a first episode of acute HF, the presence of a prior diagnosis of COPD is common, and confers a higher risk of adverse outcomes (death or readmission) during the year following discharge.
KeywordsHeart failure Chronic obstructive pulmonary disease Hospitalizations Readmissions Mortality
This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Statement of human and animal rights
This article does not contain any studies with animals performed by any of the authors. The ethics committee of the Bellvitge University Hospital approved the overall protocol.
For this type of study formal consent is not required.
- 2.Hillas G, Perlikos F, Tsiligianni L, Tzanakis N (2015) Managing comorbidities in COPD. Int J Chronic Obstr Pulm Dis 10:95–109Google Scholar
- 3.Staszewsky L, Cortesi L, Tettamanti M, Dal Bo GA, Fortino I, Bortolotti A, Merlino L, Latini R, Roncaglioni MC, Baviera M (2016) Outcomes in patients hospitalized for heart failure and chronic obstructive pulmonary disease: differences in clinical profile and treatment between 2002 and 2009. Eur J Heart Fail 18:840–848CrossRefPubMedGoogle Scholar
- 10.Canepa M, Temporelli PL, Rossi A, Rossi A, Gonzini L, Nicolosi GL, Staszewsky L, Marchioli R, Maggioni AP, Tavazzi LI, GISSI-HF Investigators (2017) Prevalence and prognostic impact of chronic obstructive pulmonary disease in patients with chronic heart failure: data from the GISSI-HF trial. Cardiology 136:128–137CrossRefPubMedGoogle Scholar
- 13.Aryal S, Diaz-Guzman E, Mannino DM (2014) Influence of sex on chronic obstructive pulmonary disease risk and treatment outcomes. Int J Chronic Obstr Pulm Dis 9:1145–1154Google Scholar
- 18.Staszewsky L, Wong M, Masson S, Barlera S, Carretta E, Maggioni AP, Anand IS, Cohn JN, Tognoni G, Latini R, Valsartan Heart Failure Trial Investigators (2007) Clinical, neurohormonal, and inflammatory markers and overall prognostic role of chronic obstructive pulmonary disease in patients with heart failure: data from the Val-HeFT heart failure trial. J Card Fail 13:797–804CrossRefPubMedGoogle Scholar
- 19.Hawkins NM, Huang Z, Pieper KS, Solomon SD, Kober L, Velazquez EJ, Swedberg K, Pfeffer MA, McMurray JJ, Maggioni AP, Valsartan in Acute Myocardial Infarction Trial Investigators (2009) Chronic obstructive pulmonary disease is an independent predictor of death but not atherosclerotic events in patients with myocardial infarction: analysis of the Valsartan in Acute Myocardial Infarction Trial (VALIANT). Eur J Heart Fail 11:292–298CrossRefPubMedPubMedCentralGoogle Scholar
- 20.Hawkins NM, Wang D, Petrie MC, Pfeffer MA, Swedberg K, Granger CB, Yusuf S, Solomon SD, Ostergren J, Michelson EL, Pocock SJ, Maggioni AP, McMurray JJ, CHARM Investigators Committees (2010) Baseline characteristics and outcomes of patients with heart failure receiving bronchodilators in the CHARM programme. Eur J Heart Fail 2010(12):557–565CrossRefGoogle Scholar
- 25.Mozzini C, Di Dio Perna M, Pesce G, Garbin U, Fratta Pasini AM, Ticinesi A, Nouvenne A, Meschi T, Casadei A, Soresi M, Cominacini L (2018) Lung ultrasound in internal medicine efficiently drives the management of patients with heart failure and speeds up the discharge time. Intern Emerg Med 13:27–33CrossRefPubMedGoogle Scholar
- 26.Marcun R, Stankovic I, Vidakovic R, Farkas J, Kadivec S, Putnikovic B, Ilic I, Neskovic AN, Lainscak M (2011) Prognostic implications of heart failure with preserved ejection fraction in patients with an exacerbation of chronic obstructive pulmonary disease. Intern Emerg Med 11:519–527CrossRefGoogle Scholar